Patients
-
NOVITÀ
TIF Signs Agreement With Resonance Health To Deploy FerriSmart®
FerriSmart is an AI-driven system for automated real-time measurement of liver-iron concentrate (LIC) in patients, using non-invasive MRI-based technology. Under the Letter of Agreement, TIF will engage with National Thalassaemia…
Leggi di più » -
NOVITÀ
La Repubblica: Gene Editing Cured Two Siblings With Thalassaemia In Italy
Cured of thalassemia, thanks to gene editing. According to a recent news report published in the Italian newspaper La Repubblica, Erika and Emanuele Guarini, two siblings from Pistoia, Tuscany, aged…
Leggi di più » -
NOVITÀ
-
Clinical News
TIF Releases New Scientific Bulletin To Highlight Research On Haemoglobin Disorders
A key objective of the Thalassaemia International Federation is to inform and update regularly the global haemoglobinopathies family, both patients and physicians, on the progress and new developments that arise…
Leggi di più » -
Global Forum
1st GLOBAL FORUM ON ACCESS TO SAFE BLOOD PRODUCTS | 5 November 2021
Expected Outcomes An understanding of the strategic vision and goals for blood safety and the protection of the blood supply, especially in low-income settings; A better understanding of the key…
Leggi di più » -
NOVITÀ
COMING UP: 1st Global Forum On Access To Safe Blood Products For Patients In Need Of Regular Transfusion – 5 November 2021
Expected Outcomes An understanding of the strategic vision and goals for blood safety and the protection of the blood supply, especially in low-income settings; A better understanding of the key…
Leggi di più » -
NOVITÀ
-
NOVITÀ
Thalassemia Foundation of Canada to Host its National Thalassemia Conference on October 23-24
The Thalassemia Foundation of Canada, a long-time member of TIF, will be holding its 2-day Virtual National Conference on Thalassaemia this weekend, October 23-24, at 12:00-16:00 EDT. The Conference aims at…
Leggi di più » -
Press Releases
Juggling Between The Cost And Value of New Therapies: Does Science Still Serve Patient Needs?
In the aftermath of the withdrawal of Zynteglo, the first gene therapy for patients with β-thalassaemia, from Europe, TIF´s Executive Director, Dr Androulla Eleftheriou, reflects on the viability of the…
Leggi di più » -
NOVITÀ
Coming Up This Thursday: Discussion On Access To Innovative Therapies – The Reblozyl Case
After receiving numerous questions from patients regarding the innovative treatment for β-thalassaemia Reblozyl (luspatercept), approved for use in the US, Europe, and Canada, TIF proceeds to organise an interactive, online…
Leggi di più »